FutureChem Co

FutureChem Co Enterprise Value

The Enterprise Value (EV) of FutureChem Co (220100.KQ) as of Oct 21, 2026 is 484.32 B KRW. In the previous year, Enterprise Value (EV) was 461.09 B KRW — a change of 5.04% (higher).

Enterprise Value

484.32 BKRW

YoY

5.04%

Last updated:

Enterprise Value (EV) of FutureChem Co is 2025 484.32 B KRW. Enterprise Value (EV) of FutureChem Co was 2024 461.09 B KRW. It decreases by 5.04% higher compared to the previous year.

The FutureChem Co Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
487.99 B KRW
Jan 1, 2019
491.71 B KRW
Jan 1, 2020
460.21 B KRW
Jan 1, 2021
470.35 B KRW
Jan 1, 2022
455.60 B KRW
Jan 1, 2023
462.24 B KRW
Jan 1, 2024
461.09 B KRW
Jan 1, 2025
484.32 B KRW
The FutureChem Co Enterprise Value history
YEAREnterprise ValueYoY
484.32 BKRW+5.04%
461.09 BKRW-0.25%
462.24 BKRW+1.46%
455.60 BKRW-3.13%
470.35 BKRW+2.20%
460.21 BKRW-6.41%
491.71 BKRW+0.76%
487.99 BKRW+2.07%
478.10 BKRW+3.51%
461.87 BKRW-10.57%
516.47 BKRW+4.11%
496.09 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

FutureChem Co Stock analysis

What does FutureChem Co do? FutureChem Co., Ltd. generates revenue through the manufacture and distribution of radiopharmaceuticals, including diagnostic agents for lung cancer, Parkinson's disease, and Alzheimer's disease. The company produces medical automation modules such as cubes, disposable cassettes, reagent kits, radio-caps, and kryptofix kits, alongside PET and SPECT precursors for radiopharmaceuticals. These products are sold to healthcare providers, diagnostic centers, and medical facilities requiring specialized radiopharmaceutical solutions. The firm also develops metal chelating agents and fluorescence probes for medical applications. The primary buyers of FutureChem's products include hospitals, clinics, and research institutions focused on cancer diagnostics and neurological conditions. Medical automation modules and disposable goods are utilized in diagnostic procedures, while PET and SPECT precursors support imaging technologies. Metal chelating agents and fluorescence probes are integrated into medical testing and imaging processes. FutureChem's revenue streams are driven by the demand for advanced diagnostic tools in oncology and neurology. The company's portfolio targets healthcare segments requiring early detection of diseases, with products designed for both diagnostic imaging and laboratory testing. Sales are concentrated in medical facilities that prioritize precision diagnostics and specialized treatment planning. FutureChem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about FutureChem Co stock

Enterprise Value (EV) of FutureChem Co is 484.32 B KRW in 2025.

Enterprise Value (EV) of FutureChem Co changed from 461.09 B KRW to 484.32 B KRW, representing a 5.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) FutureChem Co since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s KRW, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' KRW varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s FutureChem Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — FutureChem Co

All Key Metrics — FutureChem Co